Oncolytics Biotech is trading 5.9% down at $0.72, reflecting unexplained selling; no clear company-specific catalyst was identified for September 22, 2026.
- The latest company announcement found was September 10 positive preclinical data involving pelareorep and a pan-RAS inhibitor, which predates today’s decline.
- The broader biotechnology sector is rising, while major indexes are mixed; sector strength does not explain the underperformance, and no qualifying company announcement was located.